Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients

Table 2

The comparison of baseline and the change of ASL/ALT level.

	Control group (IU/mL); median (range)	Study group (IU/mL); median (range)	value
AST1	56 (20–313)	49 (21–102)	0.215
ALT1	56 (15–232)	46 (14–176)	0.087
AST2-AST1	3 (−264–283)	−3 (−43–42)	0.139
ALT2-ALT1	0 (−211–376)	−3 (−94–81)	0.443

Note: AST1/ALT1 as the first point of detection before treatment and AST2/ALT2 as the second point of detection after treatment.
The change of liver function was measured according to deviation in these values (denoted as “AST2-ASL1” or “ALT2-ALT1”). ALT: alanine aminotransferase; AST: aspartate aminotransferase.